topic

266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC)
Sophie Wildsmith, Jill Walker, Anne L’Hernault, Weimin Li, Hannah Bye, Philip He, Feng Xiao, Qu Zhang, Ross Stewart, Melissa de los Reyes, Rajiv Raja, Wendy Levin, Ashok Gupta, Thomas Powles, Joaquim Bellmunt, Matthew Galsky, Alexandra Drakaki, Michiel van der Heijden

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A163-A164; DOI: 10.1136/jitc-2020-SITC2020.0266
267 Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer
David O’Malley, Waldo Ortuzar Feliu, Isabelle Ray-Coquard, Michael O’Neal, Jerome Alexandre, Julie Cole, Robert Ludwig, Madhavi Nallewar, Jennifer Buell, Remigiusz Kaleta, Anna Wijatyk, Victoria Borisovskaya

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A164; DOI: 10.1136/jitc-2020-SITC2020.0267
272 Use of LioCyx-M, autologous hepatitis B virus (HBV)-Specific T cell receptor (TCR) T-cells, in advanced HBV-related hepatocellular carcinoma (HCC)
Fu-Sheng Wang, Fanping Meng, Jiehua Jin, Yuanyuan Li, Regina Wanju Wong, Anthony Tanoto Tan, Tingting Wang, Antonio Bertoletti

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A166-A167; DOI: 10.1136/jitc-2020-SITC2020.0272
273 Phase i study of LioCyx-M, autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, in recurrent HBV-related hepatocellular carcinoma (HCC) post-liver transplantation
Wenjie Chen, Jintao Cheng, Xiaofang Zheng, Fan Yang, Royce Fam, Sarene Koh, Lu-En Wai, Tingting Wang, Antonio Bertoletti, Qi Zhang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A167; DOI: 10.1136/jitc-2020-SITC2020.0273
277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy
Boris Sepesi, Erin Corsini, Annikka Weissferdt, Apar Pataer, Mehmet Altan, Mara Antonoff, George Blumenschein, Yasir Elamin, Frank Fossella, Bonnie Glisson, Wayne Hofstetter, Jonathan Kurie, Xiuning Le, Cheuk Hong Leung, Heather Lin, Charles Lu, Reza Mehran, Frank Mott, David Rice, Jack Roth, Ferdinandos Skoulidis, Stephen Swisher, Anne Tsao, Ara Vaporciyan, Garret Walsh, Jianjun Zhang, Don Gibbons, John Heymach, Tina Cascone

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A169; DOI: 10.1136/jitc-2020-SITC2020.0277
32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study
Abdul Rafeh Naqash, Alessio Cortellini, Emma Mi, Sanna Livanainen, Daria Gramenitskaya, James Clark, Kevin O’Brien, Jussi Koivunen, Shravanti Macherla, Sweta Jonnalagadda, Shanker Polsani, Rahim Jiwani, Nitika Sharma, Chipman Stroud, Mahvish Muzaffar, Paul Walker, David Pinato

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A18; DOI: 10.1136/jitc-2020-SITC2020.0032
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study
Karl Lewis, Paolo Ascierto, Caroline Robert, Rodrigo Munhoz, Gabriella Liszkay, Luis De La Cruz Marino, Judit Olah, Paola Queirolo, Jacek Mackiewicz, Kalpit Shah, Harper Forbes, Christian Hertig, Yibing Yan, Ralf Gutzmer, Grant McArthur

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A188-A189; DOI: 10.1136/jitc-2020-SITC2020.0307
308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma
Jeffrey Weber, Paolo Ascierto, Mark Middleton, Delphine Hennicken, Roberto Zoffoli, Anne Pieters, Adenike Amadi, Katrin Kupas, Srividya Kotapati, Andriy Moshyk, Dirk Schadendorf

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A189-A190; DOI: 10.1136/jitc-2020-SITC2020.0308
310 The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma
Anne O’Shea, Robert Chick, Guy Clifton, Timothy Vreeland, Lexy Adams, Patrick McCarthy, Phillip Kemp Bohan, Annelies Hickeron, John Myers, Jessica Cindass, Tommy Brown, Diane Hale, Mark Faries, John Hyngstrom, Adam Berger, James Jakub, Jeffrey Sussman, Montaser Shaheen, Thomas Wagner, George Peoples

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A191; DOI: 10.1136/jitc-2020-SITC2020.0310
312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition
Ahmad Tarhini, Ni Kang, Sandra Lee, F Stephen Hodi, Gary Cohen, Omid Hamid, Laura Hutchins, Jeffrey Sosman, Harriett Kluger, Zeynep Eroglu, Henry Koon, Donald Lawrence, Kari Kendra, David Minor, Carrie Lee, Mark Albertini, Lawrence Flaherty, Teresa Petrella, Howard Striecher, Vernon Sondak, John Kirkwood

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A192-A193; DOI: 10.1136/jitc-2020-SITC2020.0312

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages